Hypocalcemia in a dialysis patient treated with deferasirox for iron overload

Am J Kidney Dis. 2008 Sep;52(3):587-90. doi: 10.1053/j.ajkd.2008.03.034. Epub 2008 Jun 5.

Abstract

Deferasirox is a new iron chelator approved recently for chelation therapy in iron-overloaded patients. It is considered safe and efficacious in most patients, but has not been tested formally in patients with end-stage renal disease. We report a case of a patient with end-stage renal disease secondary to sickle cell nephropathy who developed recurrent symptomatic hypocalcemia while on therapy and later reexposure with this medication for iron overload from long-term blood transfusions. This is the first case report of this complication with deferasirox therapy in a patient with end-stage renal disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anemia, Sickle Cell / complications
  • Anemia, Sickle Cell / therapy
  • Benzoates / adverse effects*
  • Benzoates / therapeutic use
  • Deferasirox
  • Erythropoietin / therapeutic use
  • Female
  • Humans
  • Hypertension / complications
  • Hypocalcemia / chemically induced*
  • Iron Chelating Agents / adverse effects*
  • Iron Chelating Agents / therapeutic use
  • Iron Overload / drug therapy*
  • Iron Overload / etiology
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / therapy
  • Peritoneal Dialysis / adverse effects*
  • Transfusion Reaction
  • Triazoles / adverse effects*
  • Triazoles / therapeutic use

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Erythropoietin
  • Deferasirox